CCRL2 and tuberculosis: Next, to investigate the effect of CCRL-2 deletion on TB treatment outcomes in vivo, we tested the adjunctive therapeutic efficacy of an anti-CCRL2 ADC when combined with the first-line regimen for drug-susceptible RHZE.